Century Therapeutics, Inc. (IPSC) - 10-K Summary
Business Context and Reporting Period
Company: Century Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Century is a clinical-stage biotechnology company developing allogeneic, "off-the-shelf" cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company utilizes proprietary Allo-Evasion technology to prevent host immune rejection.
Key Strategic Shifts (March 2025):
- Discontinued the ELiPSE-1 Phase 1 clinical trial of lead candidate CNTY-101 for lymphoma due to data not meeting transformational thresholds, despite encouraging tolerability and activity.
- Re-prioritized pipeline to focus on CNTY-101 for B-cell mediated autoimmune diseases (CALiPSO-1 trial) and three pre-clinical iT cell programs (CNTY-308, CNTY-341, and a solid tumor program).
- Terminated the Collaboration Agreement with Bristol-Myers Squibb (BMS), effective March 12, 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $6.6 million | $2.2 million |
| Net Loss | $(126.6) million | $(136.7) million |
| Research & Development Expenses | $107.2 million | $92.7 million |
| General & Administrative Expenses | $33.2 million | $34.7 million |
| Cash, Cash Equivalents & Investments | $220.1 million | $256.8 million |
| Accumulated Deficit | $(782.3) million | $(655.8) million |
Liquidity: As of December 31, 2024, the company held $58.4 million in cash and cash equivalents and $161.7 million in investments. Management believes these resources are sufficient to fund operations into the fourth quarter of 2026.
Material Changes vs. Prior Period
- Revenue Recognition: Collaboration revenue increased to $6.6 million from $2.2 million, driven by the acceleration of revenue recognition from the BMS agreement following its termination notice. The company expects to recognize an additional $109.2 million in Q1 2025 upon the final expiration of license option rights.
- Impairment Charges: Recorded a $4.3 million impairment of goodwill in 2024 due to a decline in market capitalization. In 2023, the company recorded a $16.4 million impairment of long-lived assets related to facility consolidation.
- Acquisition: Acquired Clade Therapeutics in April 2024 for approximately $39.7 million in total consideration (cash, stock, and contingent consideration), adding three pre-clinical iT cell programs to the pipeline.
- Financing: Raised approximately $78.4 million in gross proceeds in 2024 through a Private Placement ($60 million) and At-The-Market (ATM) offerings ($18.4 million).
Guidance, Outlook, and Risks
Outlook:
- CNTY-101: Focus has shifted entirely to autoimmune indications (SLE, Lupus Nephritis, etc.) via the CALiPSO-1 trial. The company believes the data supports this pivot due to deep B-cell depletion and favorable tolerability.
- Pipeline: Advancing pre-clinical programs CNTY-308 (CD19 CAR-iT) and CNTY-341 (CD19/CD22 dual-targeted CAR-iT) for autoimmune and malignancy indications.
- Capital Needs: While current cash runway extends to late 2026, the company anticipates needing additional financing for future commercialization and expanded clinical trials.
Key Risks:
- Nasdaq Listing Compliance: Received notice in February 2025 of non-compliance with the minimum bid price requirement ($1.00) due to stock price falling below this threshold for 30 consecutive days. The company has 180 days to regain compliance.
- Revenue Cliff: The termination of the BMS collaboration eliminates a significant revenue stream after Q1 2025, with no other product sales expected in the foreseeable future.
- Development Risk: High risk of failure in clinical trials; the company has no approved products and has never generated revenue from product sales.
- Manufacturing: Reliance on third-party manufacturers (FCDI) and the scaling of its own facility in Branchburg, NJ, presents operational risks.
Investor Verification Checklist
- Stock Price Compliance: Verify if the company has regained compliance with Nasdaq's $1.00 minimum bid price requirement by August 25, 2025, to avoid delisting.
- Q1 2025 Revenue: Confirm the recognition of the remaining $109.2 million deferred revenue from the BMS agreement in the Q1 2025 earnings report.
- Cash Burn Rate: Monitor quarterly cash flow statements to validate the runway projection into Q4 2026, especially given the cessation of BMS funding.
- CALiPSO-1 Trial Data: Track enrollment and preliminary safety/efficacy data for the autoimmune trial of CNTY-101, which is now the primary clinical focus.
- Clade Integration: Assess the progress of integrating Clade Therapeutics' iT cell platform and the status of the contingent milestone payments.